Biotechnology company Vivoryon Therapeutics N.V. (Euronext Amsterdam:VVY) on Friday presented meta-analysis results for its lead drug, varoglutamstat, a glutaminyl cyclase (QPCT/L) inhibitor with anti-inflammatory and anti-fibrotic properties that is currently being evaluated for the treatment of diabetic kidney disease.

The data combined findings from the VIVIAD and VIVA-MIND Phase 2 studies conducted in Europe and the United States. Both trials demonstrated statistically significant and clinically meaningful improvements in kidney function, as measured by eGFR, in elderly patients.

Improvements in eGFR were observed from week 24 and sustained until week 96. The meta-analysis confirmed consistent effects across both studies and highlighted a greater treatment benefit among participants with diabetes compared to those without.

Vivoryon plans to initiate a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). This study aims to further evaluate the drug's efficacy on eGFR, proteinuria, and other kidney-specific markers.